Introduction
Breast cancer is the most common cancer diagnosed among women worldwide, with an estimated 1.67 million cases diagnosed in 2012, accounting for a quarter of all new cancers in women. Breast cancer is also the most common cancer diagnosed among women aged years worldwide (1) . Further, breast cancer among premenopausal women often presents at more advanced stages and has less favorable prognosis than among postmenopausal women (2, 3), and its onset frequently coincides with caregiving responsibilities for children and/or aging parents.
Identifying contributors to breast cancer risk in younger women is critical to prevention. In the United States, incidence rates of advanced breast cancer have increased among premenopausal women in recent decades, whereas they have consistently decreased among women 60 and older during the same period (4) . Accumulating evidence supports etiologic heterogeneity between pre-and postmenopausal breast cancer. Several lifestyle factors, including childbirth (5), obesity (6) , and cigarette smoking (7) have been reported to have differential associations with breast cancer risk before and after menopause. Breast cancer subtypes, including those defined by gene expression (8) , or clinical markers including estrogen receptor (ER), progesterone receptor (PR), or HER2/neu oncogene expression, have emerged as critical considerations for risk factors associations and are differentially distributed by menopausal status (9) . Investigations of breast cancer etiologic heterogeneity require large sample sizes to have sufficient statistical power to account jointly for menopausal status and tumor subtype.
The Premenopausal Breast Cancer Collaborative Group (the Collaborative Group) was established to facilitate cohort-based analyses of risk factors for premenopausal breast cancer, both overall and according to tumor characteristics. This paper describes the formation of the Collaborative Group, the methods used for ongoing efforts, and provides the rationale for initial analyses related to pregnancy, obesity, and physical activity. The infrastructure developed to address these questions can support future investigations of additional potential risk factors.
Collaborative Group Studies
The National Cancer Institute (NCI) Cohort Consortium was formed to address the need for large-scale collaborations to pool data in cohort studies of cancer and hence to quicken the pace of research (http://epi.grants.cancer.gov/Consortia/cohort.html). The Collaborative Group was 
Eligibility
Prospective cohorts in the Cohort Consortium with at least 100 female breast cancers diagnosed during follow-up before age 55 and data collection at 2 or more time points (baseline and at least one follow-up, to allow for exposure information and menopausal status to be updated) were eligible to participate.
Participating cohorts
This report describes the 20 cohort studies (counting the European Prospective Investigation into Cancer and Nutrition, which has many cohorts within it, as a single cohort) (6, (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) 
Breast cancer ascertainment
To date, data have been received for 1,030,761 women, and include 21,766 incident invasive or in situ breast cancers diagnosed after study enrollment and before age 55 years ( Table 2) .
Across studies, cancer diagnoses are identified by linkage with city/state/provincial/regional (10, 12, 13, 23, (28) (29) (30) (31) or national (11, 12, 14, 24, 26, 32, 33) population-based cancer registries, and/or through self-report followed by medical record review (6, 10, 11, 14, 15, 25, 34, 35) . All participating studies established case ascertainment procedures and published findings related to incident breast cancer risk prior to joining the Collaborative Group.
Data exchange and harmonization
After approval by the NCI Cohort Consortium executive committee, the aims of the proposed collaboration were circulated to all Consortium members in 2013. Key exposure, covariate, and outcome information necessary to address the initial analyses and potential confounding or effect modification were identified by the Coordinating Centers. A comprehensive data request was developed to minimize the need for supplemental data requests once analyses were underway.
Complete capture of all information across exposures was not required for participation.
After confirming eligibility, cohort-specific questionnaires were reviewed to evaluate availability of variables, and a data request template was sent to cohorts that wished to participate.
Requested exposure data included: age/year of cohort entry, length of follow-up, demographic characteristics (age, race/ethnicity, education, socioeconomic status), lifestyle factors (physical activity, anthropometric characteristics, alcohol intake, smoking information, mammography use), reproductive history (menarche, menstrual cycle characteristics, gravidity, parity, pregnancy complications, infertility, breastfeeding, hormonal medications, menopausal status), benign breast disease, and family history of breast cancer. Most of these characteristics were collected at enrollment and each follow-up, as available. Breast cancer information included age at diagnosis, stage, grade, histology, and expression of ER, PR, HER2, CK5/6, or EGFR. Participating studies were asked where possible to recode their own data to fit the data request template to minimize the potential for error in the recoding or understanding of variables in their original form. However, if this was not possible due to programming support constraints or other reasons, data were sent to the Coordinating Centers in their original form with a studyspecific contact person identified to address questions from Coordinating Center programmers who reformatted the information to fit the standard definitions in the data request template.
After data transfer agreements were signed between each individual study and the Coordinating Centers, completed datasets were transferred from each individual study to the coordinating centers using secure file transfer protocols. Each cohort submitted their data to one of the two Coordinating Centers who took responsibility for data transfer and harmonization procedures.
By having two data coordinating sites, one located in the United States and the other in the United Kingdom, we were able to minimize time zone differences to facilitate rapid communication, and accommodate studies that were only able to send data to certain locations because of country-specific information governance requirements.
Data harmonization procedures were standardized across Coordinating Centers. Quality control checks were run on each dataset to identify (i) potential data inconsistencies for each questionnaire round (e.g. nulliparous women reporting more than zero births), (ii) inconsistencies between questionnaire rounds (e.g. number of births at follow-up being lower than at baseline questionnaire), and (iii) implausible values. Data checking procedures were automated with a shared program that was run at each Coordinating Center with standardized output. Each cohort was contacted regarding any issues that were identified, and clarifications or updates were incorporated into the study-specific dataset. Where issues could not be resolved, pre-established recoding rules were applied to the data. When study-specific variables could not be recoded to meet the data template formats (e.g. age at exposure was collected in categories but a continuous variable was requested), differences were documented and original data were retained for potential future use. Once the datasets were recoded to the standardized formats, data were merged to create a pooled dataset containing values from all cohorts.
Defining menopausal status
A primary issue for the Collaborative Group analyses is the definition of menopausal status during follow-up and at diagnosis. Menopausal status was contributed by cohorts at each follow-up round for which it was available. In addition, we requested at least one follow-up round after age 55 or breast cancer diagnosis (if available) to allow menopausal status to be defined retrospectively. In analyses conducted by menopausal status we will explore different lag periods to determine patterns for 'premenopausal' or 'perimenopausal' breast cancer, as menopause can be a gradual transition.
Statistical approach
Two statistical approaches are being used to analyze the data. We first examine study-specific estimates and a pooled estimate across studies using a random-effects model that weights estimates by the inverse of the study-specific variance (36) (37) (38) ). An advantage of this approach is that each study-specific estimate can be derived based on its own available covariates. Cochran's Q statistic is used to examine statistical heterogeneity between studies by comparing a weighted measure of difference between individual study estimates and the pooled estimate (39, 40) . We calculate the I 2 statistic to examine the proportion of variance that is due to between-study heterogeneity rather than chance (41) . Potential sources of heterogeneity are investigated.
Maximum flexibility for confounder adjustment and assessment of effect modification can be achieved by pooling individual-level data across cohorts. If homogeneity assumptions are not violated, we pool data into a single dataset to conduct aggregate analyses stratified by study and adjusted for potential confounders that are available in all included studies.
In both approaches, Cox regression models are used to calculate hazard ratios (HR) and 95%
confidence intervals (CI) for breast cancer (42) . Regression models are constructed with age as the time scale such that person-time is accrued from age at cohort entry until breast cancer diagnosis, age at last follow-up, or other exit age, whichever occurred first. Follow-up time is stratified by time-updated exposures obtained from follow-up questionnaires, as appropriate. We test the proportional hazards assumption for exposures of interest, and in case of time-varying associations, e.g. an interaction between attained age and the risk factor of interest, we investigate the addition of time-varying covariates in the model. In pooled analyses, potential variation in the association between exposures and breast cancer risk according to tumor subtype are assessed using Cox proportional hazards regression accounting for alternative tumor subtypes as competing risks (43, 44) .
Rationale for initial aims

Pregnancy
A "dual effect" of pregnancy on breast cancer risk has been used to describe the short-term increase in breast cancer risk observed after childbirth followed by a long-term protective effect of parity. This pattern has been reported in epidemiological studies nested within European population registries (45) (46) (47) (48) (49) and in other case-control (50-55) and cohort (56) studies.
Observational studies have reported 1.25 to 3-fold increases in breast cancer risk for up to 10 years after the last birth (2, 5). 
BMI and other anthropometrics
There is epidemiological evidence for higher BMI at premenopausal ages having a protective effect on breast cancer risk (71-73). This protective effect of premenopausal BMI is already evident with respect to higher adiposity in childhood and adolescence, and appears to be associated with a lower risk of breast cancer at both premenopausal (72, (74) (75) (76) and postmenopausal (75-77) ages. Whether further weight gain contributes additional reductions in premenopausal breast cancer risk is not entirely clear (78, 79) . A protective effect of adiposity at premenopausal ages is in contrast to the effect of adiposity at postmenopausal ages, with greater BMI after menopause associated with higher risk of breast cancer, probably through production of oestrogens by aromatase in adipose tissue (80) .
The reason for the protective effect of adiposity at premenopausal ages is unclear, although several hypotheses have been put forward. Fewer ovulatory cycles in heavier women, and consequent lower sex hormone levels, has been suggested as a potential explanation (81) .
Similarly, an effect of polycystic ovary syndrome (PCOS) has been proposed, although Nurses'
Health Study II data did not support this (72) . To find the reasons for the inverse associations with premenopausal adiposity, large study populations are needed to produce stable estimates and to stratify by potentially explanatory factors. The Collaborative Group, with its large number of cases in the pooled dataset and data on a wide range of risk factors, will be able to clarify the contribution of premenopausal adiposity to breast cancer risk, by examining which subtypes of breast cancer are affected, analyzing associations by factors such as menstrual factors, and by assessing the effect of changes in adiposity over time.
Physical activity
Physical activity is of particular interest in that it constitutes a potentially modifiable risk factor for breast and other cancers. For premenopausal women, the effect of physical activity on reducing breast cancer risk appears to be smaller and less certain than for postmenopausal women (84). However, very few studies (35, 85, 86) have published prospective data for premenopausal breast cancer risk in relation to physical activity, whereas others have published by age at breast cancer (87) (88) (89) or menopausal status at study entry (90) (91) (92) (93) , or have included premenopausal women in their study but did not publish effect estimates for these women separately (94, 95) .
The biological mechanisms through which physical activity could exert an effect in premenopausal women is less clear than in postmenopausal women, but might be through an effect on menarche, menstrual dysfunction, cycle length, endogenous hormone levels or oestrogen metabolism (96) (97) (98) . A smaller effect of physical activity in premenopausal than postmenopausal women is possible because, in contrast to postmenopausal women, in whom the protective effect of physical activity on breast cancer risk is partly through its effect on reducing adiposity, adiposity in premenopausal women has a protective effect on breast cancer risk.
Additionally, the impact of physical activity on hormone levels might be less influential among premenopausal women given their high levels of circulating hormones.
To aid prevention, information is needed on the type, frequency and intensity of exercise required to influence breast cancer risk, as well as the ages and characteristics of women for whom it is most effective. There might be periods of life during which physical activity has a higher impact than others, such as the time period between menarche and first birth (99) . There is also emerging evidence of differential effects of activity by ethnicity, normal weight, parity and family history of breast cancer, but mostly based on data from postmenopausal women (35, 89, 100) . It is a limitation, however, that physical activity information is collected in many different ways and is difficult to harmonize (101).
The Collaborative Group aims to address premenopausal breast cancer risk by frequency, intensity, type and ages of exercise, within strata defined by factors such as BMI, family history of breast cancer and age at diagnosis, and to explore specific breast cancer subtypes and stages, on a much larger scale than previously. The information gained can be used to advise young women about the extent and type of exercise that can influence their breast cancer risk.
Opportunities and challenges
The Collaborative Group is an international collaboration formed to address etiological factors for breast cancer that may be particular to, or differ in, premenopausal or perimenopausal women. By harmonizing a wide range of exposure variables across 20 studies and developing quality assurance and analysis programs, our collaboration is in a position to conduct initial analyses of pregnancy, obesity and physical activity, and to leverage the research infrastructure and established collaboration model for investigations of other risk factors.
Some limitations and challenges have emerged. Our analyses, as currently constituted, will not address premenopausal breast cancer risk after age 55. Age 55 years is approximately the 88 th percentile for age at menopause in the United States (102) and may account for an even higher proportion of the premenopausal lifespan in other countries. As in many consortia, information from the participating studies in the Collaborative Group was not collected with future pooling efforts in mind and follow-up data are not collected at standardized intervals.
Therefore, harmonization efforts must identify common data elements that are collected with minimal levels of measurement error. Identification of these elements can be complicated by questionnaires and codebooks that must be translated to a common language.
Another aspect of working on pooling cohorts that requires planning and forethought is the potential for overlap of participants between studies, for example, in Scandinavian countries with multiple cohorts that have wide geographic catchment areas. Although the existence of national identifiers makes it theoretically possible to identify women who may contribute information to more than one study in a country, the logistics for obtaining approval and merging datasets can be prohibitive. Therefore, we have worked with study investigators to identify the individual cohorts within a country with the most relevant information for specific Collaborative Group aims, and to develop strategies for excluding specific streamline data sharing models to maximize productivity and collaborative opportunity. 
